Table of Contents
ISRN Virology
Volume 2014 (2014), Article ID 263793, 6 pages
http://dx.doi.org/10.1155/2014/263793
Review Article

HIV-1 Tropism Test Evaluation: Assessment and Clinical Implications

Department of Infectious Diseases, San Raffaele Scientific Institute, Via Stamira d’Ancona 20, 20127 Milan, Italy

Received 28 February 2014; Accepted 23 March 2014; Published 7 April 2014

Academic Editors: M. Magnani and F. Pulido

Copyright © 2014 Stefania Chiappetta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Alkhatib, C. Combadiere, C. C. Broder et al., “CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1,” Science, vol. 272, no. 5270, pp. 1955–1958, 1996. View at Google Scholar · View at Scopus
  2. Y. Feng, C. C. Broder, P. E. Kennedy, and E. A. Berger, “HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor,” Science, vol. 272, no. 5263, pp. 872–877, 1996. View at Google Scholar · View at Scopus
  3. E. A. Berger, R. W. Doms, E.-M. Fenyö et al., “A new classification for HIV-1,” Nature, vol. 391, no. 6664, p. 240, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. R. M. Gulick, J. Lalezari, J. Goodrich et al., “Maraviroc for previously treated patients with R5 HIV-1 infection,” The New England Journal of Medicine, vol. 359, no. 14, pp. 1429–1441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. D. A. Cooper, J. Heera, J. Goodrich et al., “Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection,” Journal of Infectious Diseases, vol. 201, no. 6, pp. 803–813, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Raymond, P. Delobel, and J. Izopet, “Phenotyping methods for determining HIV tropism and applications in clinical settings,” Current Opinion in HIV and AIDS, vol. 7, no. 5, pp. 463–469, 2012. View at Google Scholar
  7. M. Obermeier, J. Symons, and A. M. Wensing, “HIV population genotypic tropism testing and its clinical significance,” Current Opinion in HIV and AIDS, vol. 7, no. 5, pp. 470–477, 2012. View at Google Scholar
  8. J. M. Whitcomb, W. Huang, S. Fransen et al., “Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 2, pp. 566–575, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Trinh, D. Han, W. Huang et al., “Technical validation of an enhanced sensitivity Trofile HIV co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5,” Antiviral Therapy, vol. 13, supplement 3, p. A128, 2008. View at Google Scholar
  10. T. Lengauer, O. Sander, S. Sierra, A. Thielen, and R. Kaiser, “Bioinformatics prediction of HIV coreceptor usage,” Nature Biotechnology, vol. 25, no. 12, pp. 1407–1410, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services, Bethesda, Md, USA, 2007.
  12. L. P. R. Vandekerckhove, A. M. J. Wensing, R. Kaiser et al., “European guidelines on the clinical management of HIV-1 tropism testing,” The Lancet Infectious Diseases, vol. 11, no. 5, pp. 394–407, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Zhu, H. Mo, N. Wang et al., “Genotypic and phenotypic characterization of HIV-1 in patients with primary infection,” Science, vol. 261, no. 5125, pp. 1179–1181, 1993. View at Google Scholar · View at Scopus
  14. C. Hedskog, J. Brodin, A. Heddini, G. Bratt, J. Albert, and M. Mild, “Longitudinal ultradeep characterization of HIV type 1 R5 and X4 subpopulations in patients followed from primary infection to coreceptor switch,” AIDS Research and Human Retroviruses, vol. 29, no. 9, pp. 1237–1244, 2013. View at Publisher · View at Google Scholar
  15. A. B. van't Wout, N. A. Kootstra, G. A. Mulder-Kampinga et al., “Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission,” The Journal of Clinical Investigation, vol. 94, no. 5, pp. 2060–2067, 1994. View at Google Scholar · View at Scopus
  16. C. Verhofstede, M. Nijhuis, and L. Vandekerckhove, “Correlation of coreceptor usage and disease progression,” Current Opinion in HIV and AIDS, vol. 7, no. 5, pp. 432–439, 2012. View at Publisher · View at Google Scholar
  17. S. H. Eshleman, S. E. Hudelson, R. Bruce et al., “Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains,” AIDS Research and Human Retroviruses, vol. 23, no. 12, pp. 1593–1598, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Huang, J. Toma, E. Stawiski et al., “Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals,” AIDS Research and Human Retroviruses, vol. 25, no. 8, pp. 795–802, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Frange, M.-L. Chaix, S. Raymond et al., “Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection,” Journal of Clinical Microbiology, vol. 48, no. 10, pp. 3487–3491, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Frange, J. Galimand, C. Goujard et al., “High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996–2007: the French ANRS CO06 PRIMO Cohort Study,” Journal of Antimicrobial Chemotherapy, vol. 64, no. 1, pp. 135–141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. C. de Mendoza, C. Rodriguez, F. García et al., “Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 4, pp. 698–704, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Rieder, B. Joos, A. U. Scherrer et al., “Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection,” Clinical Infectious Diseases, vol. 53, no. 12, pp. 1271–1279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Chalmet, K. Dauwe, L. Foquet et al., “Presence of CXCR4-Using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission,” Journal of Infectious Diseases, vol. 205, no. 2, pp. 174–184, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Raymond, P. Delobel, M. Mavigner et al., “CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression,” AIDS, vol. 24, no. 15, pp. 2305–2312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Hamlyn, S. Hickling, K. Porter et al., “Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection,” AIDS, vol. 26, no. 7, pp. 887–890, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Nozza, A. R. Pignataro, L. Galli et al., “Immunological recovery after 24 weeks of antiretroviral therapy in patients with X4 virus during primary HIV infection,” Journal of Acquired Immune Deficiency Syndromes, vol. 65, no. 1, pp. e27–e29, 2014. View at Google Scholar
  27. C. Charpentier, V. Joly, L. Larrouy et al., “Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial,” The Journal of Antimicrobial Chemotherapy, vol. 68, no. 3, pp. 690–696, 2013. View at Google Scholar
  28. S. Nozza, F. Canducci, L. Galli et al., “Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 5, pp. 1224–1227, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. G. J. Moyle, A. Wildfire, S. Mandalia et al., “Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection,” Journal of Infectious Diseases, vol. 191, no. 6, pp. 866–872, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. R. A. McGovern, A. Thielen, S. Portsmouth et al., “Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial,” Journal of Acquired Immune Deficiency Syndromes, vol. 61, no. 3, pp. 279–286, 2012. View at Publisher · View at Google Scholar
  31. M. M. Santoro, D. Armenia, L. Fabeni et al., “The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients,” Clinical Microbiology and Infection, vol. 18, no. 8, pp. E289–E298, 2012. View at Publisher · View at Google Scholar
  32. E. Seclén, V. Soriano, M. M. González et al., “Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy,” Journal of Infectious Diseases, vol. 204, no. 1, pp. 139–144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Waters, S. Mandalia, P. Randell, A. Wildfire, B. Gazzard, and G. Moyle, “The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen,” Clinical Infectious Diseases, vol. 46, no. 10, pp. 1617–1623, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. E. A. Berger, P. M. Murphy, and J. M. Farber, “Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease,” Annual Review of Immunology, vol. 17, pp. 657–700, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. E. R. Johnston, L. S. Zijenah, S. Mutetwa, R. Kantor, C. Kittinunvorakoon, and D. A. Katzenstein, “High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment,” Journal of Virology, vol. 77, no. 13, pp. 7682–7688, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Delobel, K. Sandres-Sauné, M. Cazabat et al., “R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 38, no. 4, pp. 382–392, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. J. C. Shepherd, L. P. Jacobson, W. Qiao et al., “Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study,” Journal of Infectious Diseases, vol. 198, no. 8, pp. 1104–1112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. R. A. McGovern, A. Thielen, T. Mo et al., “Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies,” AIDS, vol. 24, no. 16, pp. 2517–2525, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. S. G. Parisi, S. Andreis, G. Palù et al., “A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects,” BMC Infectious Diseases, vol. 13, article 314, 2013. View at Google Scholar
  40. E. Seclén, M. del Mar González, C. de Mendoza, V. Soriano, and E. Poveda, “Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 7, pp. 1493–1496, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. A. C. Paquet, O. D. Solberg, L. A. Napolitano et al., “A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease/reverse-transcriptase and co-receptor tropism database from 2003 to 2012,” Antiviral Therapy, 2014. View at Publisher · View at Google Scholar
  42. B. Simon, K. Grabmeier-Pfistershammer, A. Rieger, M. Sarcletti, B. Schmied, and E. Puchhammer-Stöckl, “HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection,” AIDS, vol. 24, no. 13, pp. 2051–2058, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. M. Caseiro, M. Nelson, R. S. Diaz et al., “Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials,” The Journal of Infection, vol. 65, no. 4, pp. 326–335, 2012. View at Publisher · View at Google Scholar
  44. P. Recordon-Pinson, S. Raymond, P. Bellecave et al., “HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 2, pp. 930–935, 2013. View at Publisher · View at Google Scholar
  45. V. Svicher, R. D'Arrigo, C. Alteri et al., “Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group,” New Microbiologica, vol. 33, no. 3, pp. 195–206, 2010. View at Google Scholar · View at Scopus